Hematologic effects of linezolid: Summary of clinical experience

被引：321

作者：

Gerson, SL

Kaplan, SL

Bruss, JB

Le, V

Arellano, FM

Hafkin, B

Kuter, DJ

机构：

[1] Case Western Reserve Univ, Div Hematol Oncol, Cleveland, OH 44106 USA

[2] Case Western Reserve Univ, Ireland Canc Ctr, BRB 3, Cleveland, OH 44106 USA

[3] Univ Hosp Cleveland, Cleveland, OH 44106 USA

[4] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA

[5] Pharmacia, Kalamazoo, MI USA

[6] Pharmacia, Peapack, NJ USA

[7] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Hematol Oncol Unit, Boston, MA USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2002年 / 46卷 / 08期

关键词：

D O I：

10.1128/AAC.46.8.2723-2726.2002

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Linezolid has been associated with reversible myelosuppression. Clinical trial data were evaluated for anemia, thrombocytopenia, and neutropenia. Thrombocytopenia and a slight increased risk for anemia were evident at greater than or equal to2 weeks of linezolid treatment. Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use.

引用

页码：2723 / 2726

页数：4

共 22 条

[1]

*AD AIDS CLIN TRIA, 1992, TABL GRAD SEV AD ADV

[2] ADVERSE REACTIONS ASSOCIATED WITH THE USE OF ORAL PENICILLINS AND CEPHALOSPORINS [J].